Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.52 |
| ▸ | CCR3 | P51677 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498904 | 1.00 | KDM4E (0.56) | KDM4EHSD17B10DRD4DRD2DRD3 | |
| SCHEMBL239528 | 0.80 | DRD4 (0.71) | DRD4DRD2DRD3KMT2ASIGMAR1 | |
| SCHEMBL239527 | 0.80 | DRD4 (0.71) | DRD4DRD2DRD3KMT2ASIGMAR1 | |
| SCHEMBL5493330 | 0.80 | TRPV1 (0.39) | KDM4E | |
| SCHEMBL31616402 | 0.79 | ALDH1A1 (0.64) | KDM4EHSD17B10DRD4DRD2DRD3 | |
| SCHEMBL31616449 | 0.79 | ALDH1A1 (0.64) | KDM4EHSD17B10DRD4DRD2DRD3 | |
| SCHEMBL31616379 | 0.78 | SIGMAR1 (0.62) | KDM4EHSD17B10DRD4DRD2DRD3 | |
| SCHEMBL31616362 | 0.78 | SIGMAR1 (0.62) | KDM4EHSD17B10DRD4DRD2DRD3 | |
| SCHEMBL31616468 | 0.77 | SIGMAR1 (0.71) | KDM4EHSD17B10DRD4DRD2DRD3 | |
| SCHEMBL31616372 | 0.77 | SIGMAR1 (0.71) | KDM4EHSD17B10DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | KDM4E 3379/4885HSD17B10 207/4885DRD4 967/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | KDM4E 3077/4885HSD17B10 145/4885DRD4 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.